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Population-level survival in follicular lymphoma (FL) is
typically presented from the time of diagnosis1,2.
Although such estimates are informative to address
questions about the prognosis at diagnosis, they may be
somewhat pessimistic due to patients who die within the
first years following diagnosis. Therefore, survival esti-
mates for patients who have survived from a specified
time since diagnosis—especially when corrected for the
life expectancy in the general population—add relevant
information related to changing survival expectations over
time (i.e., conditional relative survival; CRS). At present,
published data on CRS in FL are sparse and reasonably
outdated3,4. For this reason, in this nationwide,
population-based study, we predicted up-to-date esti-
mates of 5-year relative survival (RS) at diagnosis, and for
each additional year survived up to 10 years post-
diagnosis among contemporary diagnosed FL patients in
the Netherlands using techniques that are conceptually
similar to those that estimate the life expectancy at birth.
Nationwide since 1989, the Netherlands Cancer Reg-
istry (NCR) has an overall coverage of >95% of all
malignancies in the Netherlands5. All adult (≥18 years)
patients diagnosed with FL grades 1–3B between
2000–2017 were selected from the NCR. Patients were
followed for survival through December 31, 2019. FL was
selected from the NCR by using International Classifica-
tion of Diseases for Oncology morphology codes 9690,
9691, 9695, and 96986. Patients diagnosed at autopsy
(n= 14) were excluded. The Privacy Review Board of the
NCR approved the use of anonymous data for this study.
RS was calculated to estimate disease-specific survival as
the ratio of the patients’ overall survival to the expected
survival of equivalent groups from the general population,
matched by age, sex, and calendar year. Expected survival
was estimated according to the Ederer II method using
Dutch population life tables7. We computed 5-year RS at
diagnosis and for each additional year survived up to ten
years post-diagnosis, conditional on being alive at the
beginning of that year (i.e., CRS). CRS was estimated using
hybrid and period approaches, which were empirically
validated, to predict up-to-date survival probabilities for
patients diagnosed during the period window of interest8.
For the current study, the period window of interest was
defined as 2015–2019. Thus, the CRS estimates are based
on the survival experience of patients diagnosed between
2000 and 2017, who were alive at some point during the
follow-up interval 2015–2019 and can be interpreted as
the predicted estimates for patients diagnosed in
2015–2019. Details about both approaches are provided
in the Supplemental Methods, Supplemental Tables 1, 2
and Supplemental Figs. 1, 2A–K. Survival estimates were
computed with 95% confidence intervals (CIs) and stan-
dard errors and presented for the overall cohort and
according to sex and age (18–60, 61–70, and >70) and
disease stage at diagnosis (I–II and III–IV). Excess mor-
tality is considered minimal when survival estimates
exceed 95%. Differences in survival estimates between
subgroups were considered statistically significant when
the 95% CIs did not overlap. Analyses were performed
using STATA Statistical Software version 16.1 (StataCorp,
College Station, TX).
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A total of 9557 FL patients (median age, 62 years) were
diagnosed in the Netherlands between 2000 and 2017.
Baseline characteristics of these patients—along with
projected estimates for 5-year RS at diagnosis and 5-year
CRS at 5 and 10 years post-diagnosis according to baseline
characteristics—are presented in Supplemental Table 1.
Figure 1 depicts a graphical representation of 5-year CRS
up to ten years post-diagnosis according to baseline
characteristics.
Overall, the estimate for 5-year RS at diagnosis was 85%
and increased slightly with additional years survived,
reaching 91% at 10 years post-diagnosis (Fig. 1A). This
finding was irrespective of sex (Fig. 1B). Five-year RS
estimated at diagnosis was relatively high among patients
aged 18–60 and 61–70 years and decreased significantly
with older age (92, 87, and 74% across the three age
groups, respectively; Fig. 1C). Five-year CRS among
patients aged 18–70 years remained virtually unchanged
with additional years survived, whereas it increased
among patients aged >70 years within the first 2 years
post-diagnosis (Fig. 1C). The difference in survival at
diagnosis across stage groups disappeared at 7 years post-
diagnosis, owing to a gradual increase in CRS among
patients with stage III–IV FL (Fig. 1D).
To our knowledge, only two population-based studies
assessed CRS in FL. One study included patients diag-
nosed in the Netherlands between 1989–2008 with sur-
vival follow-up through 20093. The other study included
patients diagnosed in the U.S. between 2000–2012 with
survival follow-up through 20124. The present study thus
extends on these series by predicting survival for patients
diagnosed during 2015–2019. Five-year RS estimated at
diagnosis was higher in our study (85; 95% CI, 84–87%),
as compared to the earlier series in the Netherlands (72;
95% CI, 71–73%)3 and the U.S. study (82; 95% CI,
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Fig. 1 Five-year conditional relative survival (CRS) up to ten years post-diagnosis among adult patients diagnosed with follicular
lymphoma in the Netherlands, 2000–2017. The 5-year CRS is presented for the overall cohort (A) and according to sex (B), age at diagnosis (C),
and disease stage at diagnosis (D). The error bars for the point estimates indicate 95% confidence intervals. The point estimates of CRS are considered
reliable when the standard error (SE) is ≤5%. When the SE is above 5%, the CRS estimates are not presented.
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slight increase in CRS during follow-up that was less
pronounced as compared to other types of lympho-
mas3,4,9,10. The increase in CRS among patients with FL is
most likely accounted for by improvements in FL man-
agement during sequent periods, especially the imple-
mentation of rituximab across various lines of
therapy11,12. Notwithstanding, FL patients experience
persisting excess mortality, especially patients aged >70
years and patients with stage III–IV disease.
In contrast to our study and prior population-based
studies3,4, studies have shown that FL patients who
remain event-free 24 months (EFS24) after frontline
immunochemotherapy have no excess mortality com-
pared to the general population13. The discrepancy might
stem from the inclusion of patients in population-based
series who are not eligible for trials and who achieved and
did not achieve EFS24, thereby possibly averaging of the
prognostic effect of EFS24. Nonetheless, an increase in
CRS in the first 12–24 months after diagnosis was
objectified in other lymphomas, in which the prognostic
effect of EFS24 is more pronounced than in FL3,4,9,10.
Therefore, the proper validation of EFS24 in FL patients at
the population-level is an area for future research.
Age is a well-established prognostic factor in FL. It is
incorporated as a dichotomized parameter (i.e., ≤60 or >60
years) in the FL International Prognostic Index (FLIPI)14.
We showed that the poor prognostic effect of age was pri-
marily driven by patients aged >70 years. The substantial
excess mortality among elderly FL patients that persisted
during follow-up might be related to the reticent use of
efficacious upfront and subsequent treatments due to con-
cerns about treatment-related morbidity and mortality, the
occurrence of treatment-related sequelae, comorbidities, or
histological transformation into an aggressive lym-
phoma15,16. Novel management strategies are thus war-
ranted to reduce excess mortality in elderly patients, which,
in turn, may decrease the age-related survival gap.
The prognostic effect of disease stage at diagnosis
diminished with additional years survived due to a gradual
improvement in CRS in patients with stage III–IV FL.
This phenomenon has also been observed in prior
population-based studies3,4, and should prompt effort to
mitigate the adverse prognostic effect of advanced-stage
earlier in the disease course. Therefore, optimism for the
short-term is centered on first-line treatment with bend-
amustine plus rituximab17. However, this regimen is as yet
not approved by regulatory agencies in the Netherlands.
The strengths of our study stem from the use of a
relatively large population-based cohort that enabled the
assessment of long-term and up-to-date survival expec-
tations among FL patients who were alive at some point
during the period 2015–2019. Limitations mainly pertain
to the lack of data on prognostic factors (e.g., FLIPI), the
exact therapeutic regimen across various lines of therapy,
transformation/relapse rates (e.g., EFS24), and causes
of death.
In summary, in this nationwide, population-based study
encompassing the rituximab era, 5-year CRS among
subgroups of FL patients did not exceed 95% within 10
years post-diagnosis. This finding indicates that excess
mortality compared to the general population persists.
Encouragingly enough, the prognostic effect of disease
stage ultimately disappeared. CRS estimates provide FL
patients diagnosed in a contemporary era with essential
information about their prognosis during follow-up. This
information is also relevant to physicians and could guide
surveillance and follow-up activities.
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